natgillin/translations-raw huggingface dataset:
A transgenic animal comprising a genomic meganuclease expression construct, wherein said construct comprises an inducible expression control region operably linked to a meganuclease-encoding nucleic acid, and wherein said encoded meganuclease recognizes a meganuclease target sequence present in or proximal to an endogenous Ig locus of said transgenic animal, and wherein said endogenous lg locus has been inactivated by the action of said meganuclease, and wherein optionally the genome of said transgenic animal further comprises at least one artificial Ig locus, wherein the transgenic animal is not a human. The transgenic animal according to claim 13, wherein said transgenic animal lacks a functional endogenous Ig light chain locus, or a functional endogenous lg heavy chain locus. The transgenic animal of claim 13, wherein said transgenic animal is capable of producing immunoglobulins having a human idiotype. 
Postupak sukladno bilo kojem prethodnom patentnom zahtjevu, naznačen time, da sukladno bilo kojem prethodnom patentnom zahtjevu, nadalje obuhvaća uporabu druge megamukleaze, pri čemu druga meganukleaza prepoznaje drugu ciljnu sekvencu meganukleaze prisutnu u ili proksimalnom endogenom Ig lokusu i selektivno cijepa endogeni Ig iokus zajedno s prvom meganukazom, ali na mjestu različitom od prve meganukleaze, čime se inaktivira najmanje jedan endogem 1g lokus Transgenska ne-humana životinja, koja se može dobiti metodom sukladno zahtjevu 9, naznačena time, da Životinja sadrži: Lonajmanje jedan regulirabilni konstrukt genomskog meganukleaza ekspresije; i HM. umjetni [g lokus koji zamjenjuje endogeni Ig lokus; pri čemu je životinja sposobna proizvesti protutijelo koje ima Hudski idiotip.
The stomach-to-stomach sutures or staples are preferably provided with fixation portions exhibiting a structure, such as a net like structure, adapted to be in contact with the stomach wall to promote growth in of human tissue to secure the long term placement of the volume filling device attached to the stomach wall. 
Uređaj u skladu s bilo kojim od patentnih zahtjeva 2 do 3, naznačen time što najmanje jedan od prvog 1 drugog međudjelujućeg elementa ima strukturu koja potiče rast tkiva (213), prilagođenu da bude u kontaktu s vanjskom stijenkom želuca radi osiguravanja dugotrajne pričvršćenosti uređaja za rastezanje na stijenku želuca.
A microencapsulated bacterial consortium, according to claim 1, wherein the three strains of lactic-acid bacteria are Lactobacillus plantarum ATCC 8014, Lactobacillus sanfranciscensis ATCC 27652 and Lactobacillus brevis ATCC 14869. A microencapsulated bacterial consortium, according to claim 1, wherein the encapsulating agents are selected from the group comprising isolated protein from milk serum with 90 % protein, maltodextrin with a dextrose equivalent of 10, arabic gum, mesquite gum, sodium alginate, pectin, soy isolated protein, casein and combinations thereof. 
Mikroenkapsulirani bakterijski konzorcij, prema zahtjevu 1, pri čemu su tri soja bakterija mliječne kiseline Lactobacillus plantarum ATCC 8014, Lactobacillus sanfranciscensis ATCC 27652 i Lactobacillus brevis ATCC Mikroenkapsulirani bakterijski konzorcij, prema zahtjevu 1, pri čemu su agensi za enkapsulaciju izabrani iz skupine koja sadrži izolirani protein iz mliječnog seruma s 90 % proteina, maltodekstrin s ekvivalentom dekstroze od 10, gumu arabiku, mesquite gumu, natrijev alginat, pektin, izolirani protein soje, kazein i njihove kombinacije.
A substituted imidazo[1,2-a]pyridine of formula I or a pharmaceutically acceptable salt thereof where R is —CH2COOH or —COOH. 
Supstituirani imidazo[1,2-a]piridin formule I ili njegova farmaceutski prihvatljiva sol gdje R je -CH2COOH ili -COOH.
Accordingly, in one embodiment, the invention relates to a process wherein a compound of formula II wherein R' and R" independently represent one, two or three hydrogen, halogen, C1-6-alkyl or C2-6-alkylene and L represents a leaving group is reacted with an optionally substituted N-benzyl-4-piperidone, optionally in the presence of a metallation agent selected from alkyl lithium, alkyl magnesium or magnesium; 
BR s R" (m pri čemu R* i R" nezavisno predstavljaju jedan, dva ili tri vodika, halogen, C,.g-alkil ili C,.4-alkilen i L predstavlja odlazeću skupinu, reagira s N-benzil-4-piperidonom koji može biti po izboru supstituiran po
In another embodiment the marker vaccine of the present invention is characterised in that the serological analytical method is based upon an enzyme immunoassay (EIA), preferably an enzyme-linked immunosorbent assay (ELISA), whereby antibodies that bind specifically to either the modified and/or disease-associated TAV-epitope are used. 
10. Marker cjepivo skladu s patentnim zahtjevom 8, naznačeno time što je serološka analitička metoda temeljena na enzimskom imunoodređivanju (EIA), poželjno kompetitivnom enzimom-obilježenom imunokemijskom određivanju (ELISA), pri čemu se koriste protutijela koja se specifično vežu za bilo modificirani i/ili s bolešću povezani TAV- epitop.
The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein in formula (I), R5 is a phenyl group, a thienyl group, a naphthyl group, a dihydrobenzofuranyl group, a benzodioxolyl group, a benzothiadiazolyl group, a benzothienyl group or a quinolinyl group, each of which may be substituted with 1 to 3 substituents selected from the group F [wherein the group F consists of a C1-C6 alkyl group, a halogen atom, a trifluoromethyl group, a C1-C6 alkoxy group, a nitro group, a cyano group, and a C2-C7 alkanoyl group], or a C2-C8 alkenyl group which may be substituted with a phenyl group(s). 
HR P20120363 T1 morfolino skupinu, piperazino skupinu koja može biti supstituirana sa C,-C4 alkil skupinom(ama), Cj-Cg alkanoilamino skupinu, te Ci-Cg alkilsulfonilamino skupinu], R* predstavlja atom vodika ili C,-Cg alkilnu skupinu, i R* predstavlja fenilnu skupinu, tienil skupinu, tiazolil skupinu, piridil skupinu, naftil skupinu, indanil skupinu, dihidrobenzofuranil skupinu, benzodioksolil skupinu, benzotiadiazolil skupinu, benzotienil skupinu ili kinolinil skupinu, od kojih svaka može biti supstituirana sa 1 do 5 supstituenta odabranih iz skupine € [pri čemu skupina C sadrži C,-C4 alkilnu skupinu, atom halogena, trifluorometilnu skupinu, C;,-C4 alkoksi skupinu, trifluorometoksi skupinu, nitro skupinu, cijano skupinu, te C2-C; alkanoil skupinu], ili C,-Cg alkenil skupinu koja može biti supstituirana sa fenil skupinom(ama)).
The degree of compression on the leg of the user that can be obtained with the hosiery item according to the invention or which the hosiery item is adapted to provide is preferably comprised between 18 and 60 mm Hg. 
Stupanj kompresije na nogu korisnika koji se može dobiti sa čarapom prema izumu, ili koji tako prilagođena čarapa može osigurati, nalazi se ponajprije između 18 i 60 mm Hg.
from a compound of the Formula VII: 
Datum objave europske prijave patenta:
In another variant, the chemical trigger is a product arising upon polymerization of the resin base. 
U sljedećoj inačici je kemijski triger produkt koji nastaje nakon polimerizacije baze za smolu.
A delayed release drug formulation as claimed in any of the preceding claims, wherein said buffer agent is present in said inner layer in an amount from 0.1 to 20 wt %, based on the dry weight of the third polymeric material. 
Formulacija lijeka s produljenim oslobađanjem za koju se traži zaštita patentom u bilo kojem od prethodnih patentnih zahtjeva, pri čemu je treći polimerni materijal topiv u vodi neovisno od pH.
The method according to claim 1, wherein the xerostomia is associated with cancer chemotherapy treatment. 
Betanekol za uporabu prema zahtjevu 1, pri čemu je kserostomija povezana s kemoterapijskim liječenjem raka.
Gluing those channel parts can be carried out, for instance, by pressing those channel parts 7 by their glue surfaces 10 (see Fig. 1) against or into the as yet uncured polyurethane resin and, if desired, additionally covering the channel parts with a (thin) layer of polyurethane resin. 
Sljepljivanje tih dijelova kanala može se provesti, na primjer, pritiskom tih dijelova kanala 7 s njihovim ljepljivim površinama 10 (vidi sliku 1) na ili u za sada još neumreženu poliuretansku smolu i, po želji, dodatno, pokrivanjem dijelova kanala s (tankim) slojem poliuretanske smole.
and R3 are taken together with the carbon to which they are attached to form a C3-6 carbocyclic ring; or R2 and R3 are taken together with the carbon to which they are attached to form a C3-6 heterocyclic ring; and R9 is selected from: 
–halo; i i R3 se koriste zajedno s ugljikom na kojega su priključeni, za tvorbu C3-6 karbocikličkog prstena; ili i R3 se koriste zajedno s ugljikom na kojega su priključeni, za tvorbu C3-6 heterocikličkog prstena; i
A process for creating a mixed turf (1) as claimed in one or more of the preceding claims, wherein said synthetic turf (2) is laid first and then said natural grass (3) is introduced. 
Postupak proizvodnje mješovitog travnjaka (1) prema zahtjevu 13, naznačen time da navedena prirodna trava (3) se priprema u rasadnicima i zatim se presađuje na navedeni travnjak (1).
Anti-Drug Antibodies directed against said therapeutic antibody; to obtain a patient profile, wherein the patient profile indicates whether the patient responds to the treatment or not, allowing an adjustment of the treatment. 
- - protutijela na lijek usmjerenog naspram navedenog terapijskog protutijela; zbog dobivanja profila pacijenta, pri čemu profil pacijenta ukazuje odgovara li pacijent na navedeno liječenje, omogućavajući prilagodbu liječenja.
According to one possibility of the invention, the sampler itself is provided with sample containing means. 
U skladu s jednom mogućnošću ovog izuma, sama naprava za uzimanje uzorka je snabdjevena sa sredstvom koje sadržava uzorak.
A developer supply container according to claim 1, further comprising a nozzle portion connected to the pump portion, the nozzle portion having an opening at a free end therein, with the opening of the nozzle portion being adjacent to the discharge opening. 
Spremnik za nadopunjavanje razvijača u skladu s bilo kojim od patentnih zahtjeva 1-18, naznačen time što dodatno sadrži mlaznicu (52), povezanu s navedenim crpnim dijelom (2a), te koja ima otvor na svojem slobodnom kraju, gdje je otvor navedene mlaznice (47) uz navedeni otvor za ispuštanje (3a).
means for feeding biogas for supplying the remaining part (6) of said biogas stream (2) to at least said treatment units (U1, U2); 
- < punjač bioplina, namijenjen dostavljanju preostalog dijela (6) navedene struje bioplina (2) u najmanju ruku navedene jedinice za obradu (U1, U2);
A developer supply container according to claim 9, wherein said nozzle portion (47) is provided with a plurality of further openings (51) around a free end side thereof. 
Spremnik za nadopunjavanje razvijača u skladu s patentnim zahtjevom 19, naznačen time što navedena mlaznica (47) ima više otvora (51) oko svoje strane sa slobodnim krajem.
A sludge drying bed (14) according to claim 1, wherein: 
Ležište za sušenje mulja (14) u skladu s patentnim zahtjevom 1, naznačeno time što:
Preferably, the present composition is essentially completely water soluble up to a dry solids content of at least 0.01 wt.%, more preferably up to a dry solids content of at least 0.05 wt.%, most preferably up to 0.1 wt.%. 
Poželjno, sadašnji pripravak je uglavnom potpuno topljiv u vodi do sadržaja suhe tvari od najmanje 0,01 mas.%, poželjnije do sadržaja suhe tvari od najmanje 0,05 mas.%, najpoželjnije do 0,1 mas.%.
n is an integer from 1 to 4; and ring A is a benzene ring, pyridine ring or piperidine ring. 
n je cijeli broj od 1 do 4; i Prsten A je benzenski prsten, piridinov prsten ili piperidinov prsten.
Imazamox, including its respective isomers a s well as its respective environmentally compatible salts or esters or amides or other derivatives; and 
A) imazamoks, uključujući njegove odgovarajuće izomere kao i njegove odgovarajuće sa životnom sredinom kompatibilno soli, estere, amide ili druge derivate; i
A method according to claim 14 or claim 15 wherein the GPR119 agonist has an EC50 of less than 100 nM. 
Pripravak u skladu sa zahtjevom 1, naznačen time, da DPP-IV inhibitor ima IC50 manji od 100 nM.
A pharmaceutical aerosol solution composition according to claim 7 wherein the overall formoterol degradation products level is lower than 2% w/w with respect to the theoretical formoterol fumarate content of 6mg/actuation and the residual level of the formoterol fumarate is higher than 95% w/w with respect to its initial content. 
Farmaceutski pripravak aerosolne otopine prema patentnom zahtjevu 13 u kojem je ukupna razina degradacijskog produkta formoterola niža od 2% w/w prema teorijskom sadržaju formoterol-fumarata od 6 ug/aktiviranju, a preostala razina formoterol-fumarata je viša od 95% w/w prema njegovom početnom sadržaju.
The present invention relates to a monoclonal antibody, or a divalent functional fragment or derivative thereof, capable to inhibit the c-Met dimerization, said antibody comprising a heavy chain comprising CDR-H1, CDR-H2 and CDR-H3 with respectively the amino acid sequences SEQ ID Nos. 1, 2 and 3; and a light chain comprising CDR-L1, CDR-L2 and CDR-L3 with respectively the amino acid sequences SEQ ID Nos. 5, 6 and 7, said antibody being further characterized in that it also comprises a hinge region comprising the amino acid sequence SEQ ID No. 21. 
HR P20181868 T1 PATENTNI ZAHTJEVI Monoklonalno antitijelo, ili njegov dvovalentni funkcionalni fragment, koji može inhibirati dimerizaciju c-Met, rečeno antitijelo ili njegov dvovalentni funkcionalni fragment, sadrži teški lanac koji sadrži CDR-H1, CDR-H2 te CDR-H3 s aminokiselinskim sekvencijama SEQ ID Nos. 1, 2 1 3; te laki lanac koji sadrži CDR-L1, CDR-L2 i CDR-L3 s aminokiselinskim sekvencijama SEQ ID Nos. 5, 6 1 7, rečeno antitijelo ili njegov dvovalentni funkcionalni fragment, dalje naznačeno time da: i)
The pharmaceutical composition for use as claimed in any of Claims 1 to 3, wherein the hyaluronic acid has an average molecular weight ranging from about 300,000 to about 6,000,000 Dalton. 
Farmaceutski sastav za uporabu prema bilo kojem od zahtjeva 1 do 3, naznačen time, da hijaluronska kiselina ima prosječnu molekularnu masu u rasponu od oko 300 000 do oko 6 000 000 Daltona.
1 represents such a sanding element in the form of a laminated disc 1 . 
Slika 1 prikazuje takav element za brušenje koji ima oblik lameliranog diska 1.
adding a composition comprising a reactive molecule selected from the group consisting of water, a lower alkyl monohydric alcohol, hydrogen sulfide and a lower alkyl monobasic amine to the composition comprising the active carbonate ester of a water-soluble polymer and unreacted di(1-benzotriazolyl)carbonate, wherein the composition comprising the reactive compound is added such that substantially all of the unreacted di(1-benzotriazolyl)carbonate is substantially consumed; 
(b) dodavanje, prije rekuperacije aktivnog karbonatnog estera vodotopljivog polimera, kompozicije, koja sadrži reaktivnu molekulu izabranu iz grupe koja se sastoji od vode, nižeg alkil monohidroksilnog alkohola, vodikova sulfida i nižeg alkil monobaznog amina, kompoziciji koja sadrži aktivni karbonatni ester vodotopljivog polimera i neizreagirani p-nitrofenil kloroformat, pri čemu se kompozicija koja sadrži reaktivnu molekulu dodaje tako da se potroši više od 50% neizreagiranog p-nitrofenil kloroformata.
A process for preparing a compound according to claim 1, comprising reacting a compound according to claim 13 or 14 with a compound of the formula 
Postupak dobivanja spoja u skladu s patentnim zahtjevom 1, naznačen time što se sastoji u reakciji spoja u skladu s patentnim zahtjevom 13 ili 14 sa spojem formule Rz
is independently selected from the group consisting of R'O- (R')2N-; 
je odabran iz skupine koju čine: halogen- cijano- nitro-
Nucleic acid molecule comprising a nucleic acid sequence coding for the B chain of human follicle stimulating hormone (FSH), which is the coding region of the nucleic acid sequence according to SEQ ID No. 
Molekula nukleinske kiseline koja obuhvaća sekvencu nukleinskih kiselina koja kodira B lanac humanog folikulo stimulirajućeg hormona (FSH), a to je kodirajuća regija sekvence nukleinskih kiselina prema SEQ ID No.
is -OH; R6 is hydrogen; and is hydrogen, provided that R2 and R3 cannot both be hydrogen when R4 is halogen. 
je vodik, halogen ili -CH3, pod uvjetom da R2 i R3 ne mogu oba biti vodik kada R4 je halogen, R7 je -OH i R8 je vodik;
An agricultural composition for combating animal pests comprising at least one compound of claim 1 and at least one inert liquid and/or solid acceptable carrier and, if desired, at least one surfactant. 
Poljoprivredna kompozicija za borbu protiv životinja štetočina koja sadrži najmanje jedan spoj prema bilo kojem od patentnih zahtjeva 1 do 11 i najmanje jedan inertni tekući i/ili čvrsti prihvatljivi nosač i, ako je poželjno, najmanje jedan surfaktant.
The compound for use of claim 12 wherein the second agent: 
Spoj za upotrebu prema zahtjevu 12, pri čemu drugo sredstvo:
The syringe of claim 9, wherein the barrel of the syringe contains an injectable suspension comprising leuprolide acetate. 
Å trcaljka u skladu s patentnim zahtjevom 9, naznačena time što cilindar štrcaljke sadrži injekcijsku suspenziju koja sadrži leuprolid-acetat.
The modular system as claimed in claim 4, wherein a corresponding one of said first and second connecting devices of said elongated base comprises a securing device cooperating with the corresponding connecting device of the corresponding end of said neighboring elongated base for securing said elongated base and said neighboring elongated base together. 
Modularni sustav prema zahtjevu 3, gdje jedan odgovarajući od navedenih prvih i drugih spojnih dijelova duguljaste baze (100) obuhvaća povezujuću napravu koja zajedno s odgovarajućim spojnim dijelom odgovarajućeg kraja susjedne duguljaste baze (906) služi međusobnom učvršćivanju duguljaste baze (100) 1 susjedne duguljasto baze (906).
The field has a predetermined number of bits. 
Broj objave europskog patenta:
In yet another embodiment of the dosage form, the dosage form comprises 45.0 mg of mannitol, 0.4 mg of aerosil, 5.0 mg of starch NF, 20.0 mg of pregelatinized starch, 1.5 mg of stearic acid, 1.5 mg of talc, 3.5 mg of hypromellose, 4.0 mg of methacrylic acid ethyl acrylate copolymer, 0.8 mg of triethyl citrate, and 1.9 mg of talc extra fine. In yet another embodiment of the dosage form described herein, the content of rasagiline is 0.5 mg. 
Oblik doziranja prema bilo kojem od patentnih zahtjeva 1-3, naznačen time, da je jezgra u obliku tablete, kod čega je sadržaj rasagilina 1,0 mg, a tableta sadrži 45,0 mg manitola, 0,4 mg aerosila, 5,0 mg škroba NF, 20,0 mg prethodno želatiniranog škroba, 1,5 mg stearinske kiseline, 1,5 mg talka, 3,5 mg hipromeloze, 4,0 mg kopolimera metakrilna kiselina - etil akrilat, 0,8 mg trietil citrata, 1,9 mg ekstra finog talka i 2,0 mg agensa za boju obloge.
The then isolated, crystalline [1-hydroxy-2-(3-pyridinyl)ethylidene]bisphosphonic acid is suspended in water, and 45% aqueous sodium hydroxide is added. 
Nakon izolacije, [1-hidroksi-2-(3-piridiniljetiliden] bisfosfonska kiselina se supsendira u vodi i doda 45 % natrijeva lužina.
wherein R1c is as defined above, to obtain a compound represented by the formula (IX): 
Run) pri čemu je R" definiran kao gore, da se dobije spoj predstavljen formulom (IX):
The ophthalmic solution according to claim 1, wherein the N—(N-acetylcysteinyl-)chitosan or pharmaceutically acceptable salt thereof used for the preparation of the solution exhibits at a concentration of 0.5% in water at 25° C. a kinematic viscosity within the range of 1 to 15 mm2/s. 
Oftalmološka otopina prema bilo kojem od prethodnih zahtjeva, naznačena time da N-(N-acetilcisteinil-)kitozan korišten za pripremu otopine ima pri koncentraciji od 0,5% u vodi na 25ºC kinematski viskozitet unutar raspona od 1 do 15 mm2/s, poželjno 2 do 10 mm2/s.
After 1 hr the stirred reaction was heated to 35°C for 5 hr whereupon it was allowed to cool to 20°C as the reaction stirred overnight. 
Poslije 1 sata, mješana reakcija je zagrijavana do 35*C 5 sati, nakon čega je ostavljena da se hladi do 20%C kao reakcija koja je miješana preko noći.
The crystal according to claim 6 having a diffraction angle 2θ of a main peak of powder X-ray diffraction of 17.8, 21.1, 22.5, 23.3, 24.1 and 24.4 degrees. wherein the X-ray diffraction measurement conditions are as in claim 6 
Kristal prema zahtjevu 6 naznačen time da ima glavni vršak kod difrakcije X-zraka na prahu s kutom difrakcije 20 kod 17.8, 21.1, 22.5, 23.3, 24.1 i 24.4 stupnjeva, pri čemu su X uvjeti mjerenja difrakcije X-zraka kao u zahtjevu 6.
The method of claim 6, wherein the keratin protein material is produced by isolating water insoluble keratin proteins from a keratin raw material. 
Postupak u skladu sa zahtjevom 26, naznačen time, što je materijal keratin proteina izrađen izoliranjem vodno netopljivog keratin proteina iz keratin sirovine materijala,
capable of significantly improving one or more functional measures after placement of an adequate number of NSLCs into the void in a brain ablation model; 
- < sposobna da značajno unaprijedi jednu ili više funkcionalnih mjera poslije postavljanja adekvatnog broja NSLCs u prazninu u modelu ablacije mozga;
An important object of the invention is to provide a prosthetic device for increasing the resistance of conduits selected from the group consisting of the urethra; the rectum or colon (or canalis analis); and the ureter for the treatment of urinary incontinence, anal incontinence, and vesicouretal reflux, respectively; wherein said device is injectable and comprising the hydrogel as described herein. 
Jedan važan cilj ovog izuma je taj, da se osigura protetički uređaj za povećanje otpornosti provodnih kanala koji su odabrani iz skupine koja se sastoji od mokraćne cijevi; rektuma ili debelog crijeva (ili canalis analis); i mokraćovoda za liječenje urinarne inkontinencije, analne inkontinencije odnosno vezikoureteralnog refluksa; pri čemu se navedeni uređaj može injektirati i sadržava hidrogel kao što je to ovdje opisano.
Method of manufacturing the extended release tablet formulation according to one of the preceding claims 1 to 17, via a direct compression process comprising the steps of 
Postupak priprave formulacije tablete produljenog oslobađanja u skladu s jednim od prethodnih zahtjeva 1 do 10, pomoću postupka izravnog komprimiranja, naznačen time, da sadrži slijedeće korake
decreasing the total amount of soluble AB in the brain of an animal, particularly a mammal, but especially a human suffering from an amyloid-associated disease or condition; or 
smanjivanju ukupne količine topljivog AB u mozgu životinje, osobito sisavca, no prije svega čovjeka koji boluje od bolesti ili stanja povezanog s amiloidima; ili
The freeze-dried formulation according to any one of Items 1 to 12, wherein the aripiprazole is in the form of a monohydrate. 
Zamrzavanjem osušena formulacija prema zahtjevu 1, naznačena time da je aripiprazol u obliku monohidrata. 14.
The molar ratio of 3-pyridyl acetic acid hydrochloride, phosphorus trichloride and water used in the reaction is 1:6:7.4 (moles). 
Molarni omjer hidroklorida 3-piriđinil octene kiseline, fosfor-triklorida i vode korištenih u reakciji jest 1:6:7.4 (molova).
a ball screw (48) positioned within said invert base coaxially with said axis, said ball screw having spaced oppositely threaded portions (52, 54), 
- kuglasti vijak (48) smješten unutar spomenute baze invertiranja suosno sa spomenutom osi, a spomenuti kuglasti vijak ima dva razmaknuta dijela sa suprotnim navojima (52), (54),
wherein R2 and R6 are as defined for the compound of formula (IIb); 
)-NH, R6 gdje su R2 i R6 kao što su definirani za spoj formule (IJ), i
A second, optional aluminum disc 72 with hole 74 is located at the mouth end of the aerosol generator 12. 
Drugi, opcijski aluminijski disk 72 sa otvorom 74 nalazi, se na usnom kraju sredstva 12 za generiranje aerosola.